Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

Oct 28, 2017


PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a 

Currently there are no specifically approved disease modifying therapies for children and adolescents with MS, a population at high risk of long-term disability

MS is a highly debilitating disease which touches every aspect of young patients’ daily lives, from school performance to family relations and friendships.


READ MORE — 

MS Views and News provides Multiple Sclerosis education, information, resources and services that will benefit many affected by MS. 

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews